A Phase I Study of Eribulin, a Novel Microtubule Inhibitor, in Children With Refractory or Recurrent Solid Tumors

Trial Profile

A Phase I Study of Eribulin, a Novel Microtubule Inhibitor, in Children With Refractory or Recurrent Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Eribulin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms ERIBULIN
  • Most Recent Events

    • 29 Mar 2017 Planned End Date changed from 1 Dec 2015 to 1 Jun 2018.
    • 29 Mar 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2018.
    • 10 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top